TGFBI and cholangiocarcinoma: Compared to matched normal tissues, TGFBI was upregulated in cholangiocarcinoma (CHOL; p < 0.01), colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), GBM, head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), rectum adenocarcinoma (READ), stomach adenocarcinoma (STAD), and thyroid carcinoma (THCA; p < 0.001).